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Abstract.  Glycosaminoglycan-modified isoforms of 
CD44 have been implicated in growth factor presenta- 
tion at sites of inflammation.  In the present study we 
show that COS cell transfectants  expressing CD44 iso- 
forms containing the alternatively spliced exon V3 are 
modified with heparan  sulfate (HS). Binding studies 
with three HS-binding growth factors, basic-fibroblast 
growth factor (b-FGF), heparin binding-epidermal 
growth factor (HB-EGF), and amphiregulin,  showed 
that the HS-modified CIM4 isoforms are able to bind 
to b-FGF and HB-EGF, but not AR. b-FGF and 
HB-EGF binding to HS-modified CD44 was elimi- 
nated by pretreating the protein with heparitinase  or 
by blocking with free heparin.  HS-modified CD44 im- 
munoprecipitated from keratinocytes, which express a 
CD44 isoform containing V3, also bound to b-FGF. 
We examined whether HS-modified CD44 isoforms 
were expressed by activated endothelial cells where 
they might present HS-binding growth factors to leu- 
kocytes during  an inflammatory response.  PCR and 
antibody-binding studies showed that activated cultured 
endothelial cells only express the CD44H isoform 
which does not contain any of the variably spliced 
exons including V3. Immunohistological  studies with 
antibodies directed to CD44 extracellular domains en- 
coded by the variably spliced exons showed that vascu- 
lar endothelial cells in inflamed skin tissue sections do 
not express CD44 spliced variants.  Keratinocytes, 
monocytes, and dendritic cells in the same specimens 
were found to express variably spliced CD44.  3~SO4  -2- 
labeling experiments demonstrated that activated cul- 
tured endothelial cells do not express detectable levels 
of chondroitin  sulfate or HS-modified CD44.  Our 
results suggest that one of the functions of CD44 iso- 
forms expressing V3 is to bind and present a  subset 
of HS-binding proteins.  Furthermore,  it is probable 
that HS-modified CD44 is involved in the presentation 
of HS-binding proteins by keratinocytes in inflamed 
skin.  However, our data suggests that CD44 is not 
likely to be the proteoglycan principally involved in 
presenting HS-binding growth factors to leukocytes on 
the vascular cell wall. 
C 
o44 represents  a very heterogeneous  class of mole- 
cules all encoded by a single gene.  Genomic clon- 
ing  of CD44 has  revealed  that  there  are  19 exons 
(47),  12 of which can be alternatively  spliced.  At least  18 
different  CD44  transcripts  have  been  identified  and  the 
potential  for many  more exists  (for review  see 35).  The 
diversity of CD44 is further magnified by the differential use 
of numerous N-linked  and  O-linked  glycosylation  sites as 
well  as  glycosaminoglycan  (GAG)  ~ attachment  sites.  We 
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1. Abbreviations  used in this paper:  ACD, allergic contact dermatitis; AR, 
amphiregulin; b-FGF,  basic-fibroblast  growth factor; CS, chondroitin sul- 
fate; GAG, glycosaminoglycan;  HAEC, human aortic endothelial cells; HB- 
EGF,  heparin binding-epidermal growth  factor; HEP,  heparitinase; HS, 
heparan sulfate; HUVEC, human umbilical vein endothelial cells; NHEK, 
normal human epithelial keratinocytes;  OM, oncostatin; PSO,  psoriasis; 
RT-PCR,  reverse transcription polymerase chain reaction. 
have become interested in whether these numerous  isoforms 
provide  for distinct  and/or multiple  CD44 functions. 
A number of functions have been attributed  to CD44, but 
functional  characterization  of  CD44  isoforms  has  been 
limited. The extracellular  domain of CD44 clearly functions 
as a cellular adhesion molecule, capable of binding extracel- 
lular matrix components including hyaluronic acid (1, 8, 41), 
fibronectin (24) and collagen (62), and mediating homotypic 
cellular aggregation (50). Its intracellular  domain associates 
with cytoskeletal proteins ankyrin,  actin, ezrin, radixin,  and 
moesin (22, 31, 54, 59), and these interactions  are believed 
to be critical  for HA binding  and CD44-dependent cellular 
mobility on plastic  plates  coated with HA (34,  56).  CD44 
expression  on lymphocytes has been shown to be involved 
in  hematopoiesis (41), selective  homing  to mucosal lym- 
phatic  tissue (25),  and lymphocyte infiltration  into cutane- 
ous delayed type hypersensitivity  sites in mice (5). Expres- 
sion of CD44 may also be important  during  tumor growth 
and metastasis (10, 52). CD44 has been implicated in signal 
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ther CD2 or the T cell receptor results in enhanced T cell 
proliferation, induced IL-2 receptor expression, IL-2 pro- 
duction, and Ca  2+ flux (18, 46). Signaling induced by CD44 
specific HA binding in macrophages has also been shown 
(42). 
Proteoglycans have been shown to act as  reservoirs for 
growth factors in many tissues (for review see 55, 63). Char- 
acterization of the biological significance of the interaction 
between heparan sulfate (HS) and GAG-binding growth fac- 
tors has been demonstrated for the fibroblast growth factors 
(FGF) (45, 64), platelet-derived growth factor (PDGF) (43, 
44),  vascular endothelial growth factor (VEGF)  (9),  am- 
phiregulin  (AR)  (7,  49),  and  heparin  binding-epidermal 
growth factor (HB-EGF) (16, 17). Binding of growth factors 
to proteoglycans via GAG moieties has been proposed to 
provide a mechanism for growth factor recruitment at the 
cell surface, presentation to specific receptors, regulation of 
their action on target cells at short range, and establishment 
of a growth factor gradient within a tissue. These observa- 
tions are consistent with the hypothesis that GAG-modified 
CD44 isoforms might be involved in growth factor, cytokine, 
and/or chemokine presentation. This view is supported by 
an in vitro model system showing that CD44 isolated from 
monocytes can present macrophage inflammatory protein-I/3 
(MIP-1/3) to T  cells (53). 
Proteoglycan-mediated presentation of chemokines to leu- 
kocytes has  been  proposed  to  play  a  major  role  during 
inflammatory responses. Leukocyte adhesion to endothelial 
cells at sites of inflammation has been modeled as a three 
step process described as follows: selectin mediated tether- 
ing and rolling, leukocyte activation, and activation-depen- 
dent tight cell adhesion which leads to diapedesis (for recent 
reviews see 4, 32, 33, 48, 65). It has been suggested that the 
leukocyte  activation  step  involves  proteoglycan-mediated 
chemokine presentation by activated endothelial cells lining 
the inflamed vascular wall. This mechanism of chemokine 
presentation permits the establishment of a chemokine gra- 
dient along  and  across  the  endothelium and  prevents the 
chemokines  from being  swept  away  in  the blood stream. 
GAG-modified CD44  isoforms expressed by vascular en- 
dothelial cells have been proposed to participate in the pre- 
sentation of chemokines to leukocytes at sites of inflamma- 
tion (53). 
Some CD44 isoforms contain heparan sulfate, a glycos- 
aminoglycan known to bind to a wide range of growth fac- 
tors,  cytokines,  and  chemokines.  Here  we  define  which 
CD44 isoforms are modified with HS, demonstrate the abil- 
ity of HS-modified CD44 to bind to different HS-binding 
growth factors and identify cell types that use HS-modified 
CD44 for growth factor presentation. 
Materials and Methods 
Cell Culture 
Normal human epithelial keratinocytes (NHEK), human umbilical vein en- 
dothelial cells (HUVEC), and human aortic endothelial cells (HAEC) were 
all purchased from Clonetics and grown in Clonetics media (San Diego, 
CA). All primary cells were used between passage 4-8. The fibrosarcoma 
cell line HT-1080 cells, WI-38 cells (fibroblasts), and COS cells were pur- 
chased from American Type Culture Collection (Rockville, MD) and grown 
in DMEM/10%  FBS. Cells were treated with the following proinflamma- 
tory mediators: 20 ng/ml TNF-cx (R&D Systems, Minneapolis, MN), 200 
U/ml IFN-3: (R & D Systems), 1/~g/ml LPS (Sigma Immunochemicals, St. 
Louis, MO),  10  -4 M histamine (Sigma Immunochemicals), 20 ng/ml IL-I 
(R & D Systems), 2 U/ml thrombin (Sigma Immunochemicals), 20 ng/ml 
TGF-/3 (BMS-PRI, Seattle, WA), 20 ng/ml b-FGF (R &  D Systems), and 
20 ng/ml a-FGF (R &  D  Systems). 
Construction of CD44-Ig Expression Vectors 
A cassette vector was prepared in order to make soluble immunoglobulin 
fusion proteins of CD44 containing the variably spliced exons. Restriction 
sites for  cloning  in  the  alternatively  spliced  exons  were  placed  into  a 
CD44H full-length vector (pBCKS/FLCD44) as described by Jackson et 
al. (20).  Using pBCKS/FLCD44 as template, the extracellular domain of 
CD44 was PCR amplified with primers designed to allow PCR products 
to be digested with HindlIl and SphI. In a separate reaction, cDNA encod- 
ing a human IgG1  hinge and constant domains were PCR amplified from 
a 41BB-Ig expression vector (6), with primers designed to allow PCR prod- 
ucts to be digested with SphI and XbaI. In a three way ligation, these two 
PCR fragments were ligated into HindllI-XbaI cut pBCKS/FLCD44 vec- 
tor.  The PCR oligonucleotides used for amplifying CD44H were the T3 
primer and 44sphl-RP (GATCAGGCATGCTGG-AATTTGGGATGTCCT- 
TATAGG).  Amplification of the IgG domains was carried out with oligonu- 
cleotides  R'),ISphI-FP  (GCAGTCGCATGCGAGCCCAAATCTTGT 
GAC)  and  CDM7-XBAI-RP  (CCAATTATGTCACACCACAGAAGT- 
AAGG). The PCR conditions consisted of 6 min at 94°C followed by 25 
cycles of 1 rain at 94°C, 2 min at 55 °C, and 3 min at 72 °C. Taq polymerase 
and reaction condition were used as suggested by the vendor (Perkin Elmer 
Cetus, Norwalk, CT). This CD44 expression cassette was used for cloning 
in the different CD44 variably spliced exons as described by Jackson et al. 
(20). To verify the absence of PCR-induced mutations all constructs were 
sequenced. 
Metabolic Labeling and Enzymatic Digestion 
Approximately l07 cells were labeled with 1 mCi [35S]NaHSO4  (New En- 
gland Nuclear, Boston, MA) for 4 h except when stated differently in the 
text. COS cell-generated CD44-Ig was produced by using a DEAE-dextran 
procedure and the fusion proteins were purified from tissue culture super- 
natants as described by Aruffo et al. (l). CD44 from cell lines was extracted 
in  a  lysis buffer containing 0.1  M  NaCl,  0.01  M  Na2PO4  1%  Triton 
X-100, 0.5% deoxycholate, 0.1% SDS, I/~g/ml of each of the protease in- 
hibitors aprotinin, leupeptin, and pepstatin. Samples were precleared with 
25 /~l protein G  Sepharose for  1 h on ice. After the protein G Sepharose 
was spun out, 25 #g/ml of Pgp-1 (PharMingen, San Diego, CA) was added 
and incubated on ice overnight. Protein G Sepharose was added for 2 h, and 
then  washed six  times  in  cold  lysis buffer.  Enzymatic digestions were 
carried out in the presence of the protein G Sepharose. The 35SO4-CD44 
coupled to protein G was incubated for  1 h at 37°C with either  1 mU of 
Flavobacterium heparinum  Heparitinase,  or  50 mU of Proteus 1/ulgaris 
Chondroitin ABC lyase (ICN Immunobiologicals, Lisle, ILL or both. All 
samples were heated for 10 min at 95°C in 2x loading buffer with/3-mer- 
captoethanol and  ran on either 4%  SDS-PAGE gels,  or  on Tris/glycine 
4-12%  gradient gels (Novex, San Diego, CA). 
Iodination 
1.5 p.g of b-FGF (R & D Systems), AR (BMS-PRI), HB-EGF (R & D Sys- 
tems), and Oncostatin M  (OM)  (BMS-PRI)  each in 20 ~tl of PBS, were 
added in 20 t~l of 2 M KPO4 pH 7.4, 300 tzCi of ~25I (3/xl), and then 3 ~tl 
of 0.25 mg/ml Chloramine T was added to each sample, and incubated for 
2  min at RT.  The reaction was quenched by adding sequentially 1 ~1 20 
mg/ml sodium metabisulfite, 14 ~tl 300 mg/ml potassium iodide,  14 t~l 20 
mg/ml N-glycyl-tyrosine, and incubated at room temperature for 2 min. The 
mixture was then passed over a PD-10 column (Pharmacia LKB Biotechnol- 
ogy, Piscataway, NJ) and fractions were eluted with 0.5 ml of 2 mg/ml BSA 
in PBS. 
mAbs 
Anti-CD44 mAb A3D8 and A3D8-FITC (Sigma Immunochemicals) were 
added at manufacturer's recommended concentration for FACS  analysis. 
The anti-CD44V3 specific mAb was purchased from R &  D Systems and 
used at 10 #g/ml. CD44 immunoprecipitations were carried out with the 
anti-CD44  mAb pgp-I  at  l0  /xg/ml  (Pharminger,  San Diego,  CA).  The 
ELAM-1  mAb was purchased from Becton Dickinson (Mountain View, 
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an IgG1 mouse mAb provided by Jeff Ledbetter (BMS-PRI), and mouse 
IgG1,  IgG2a,  IgG2b  antibodies to  plant proteins were purchased from 
Sigma Immunochemicals. Anti-mouse-FITC (Tago, Burlingame, CA) was 
used at 1:100. The polyclonal Ab raised against the CD44 variably spliced 
exons (rabbit IgG) and mAb VFF7, VFF8 against CD44V5 and CD44V6 
(mouse lgG1) have been described previously (15, 29) and were kind gifts 
of K.-H. Heider and G. Adolf (Bender ImmuneSystems, Vienna, Austria). 
FACS A nalys~s 
Cells were lifted from plates with EDTA, washed, and added to staining 
media (RPMI/2% FBS/0.1%  azide). The cells were stained with the indi- 
cated antibodies for 30 rain at 4°C. The cells were washed two times with 
RPMI and FITC-labeled secondary antibodies were added for 30 rain at 4°C 
and washed two more times. The cells were fixed in 2 % formaldehyde/PBS 
and analyzed on a Hewlett Packard FACScan. Expression of CD44 protein 
by cultured endothelial cells was calculated by taking the mean fluorescence 
intensity of isotype-matched controls divided into the mean fluorescence of 
the experimental data point to give the fluorescence shift for stimulated and 
unstimulated cells (Fig. 4). The fluorescence shift (level of expression) of 
CD44 on unstimulated cells was set to  100%. 
Reverse Transcriptase-PCR 
eDNA for PCR was prepared by a random primer method. 10/~g of total 
mRNA was incubated with 1 #1 of 0.1 M Hexamer (GIBCO BRL) for 10 
rain at 65°C. Then 4 #1 of 5× first strand buffer (GIBCO BRL), 0.1 M DTT 
(GIBCO BRL), 2.5 M dNTP's (Boehringer Mannheim Corp.), and 1 #1 su- 
perscript RT (GIBCO BRL) was added and incubated for 1 h at 37"C. Thirty 
/~1 of dH20 was added, and then 3 #1 of the reaction volume was used for 
each PCR reaction. The PCR reactions were carried out in a total volume 
of 50 #1 with the following reagents added together: 3/~1 of eDNA, 3 ~1 
1.25 mM dNTP's (Boehringer Mannheim Corp.), 2.5 #1 of  each oligonucle- 
otide  (  10  ~M),  5  #1  10x  buffer,  and  0.5  U  Taq  DNA  polymerase 
(Boehringer Mannheim Corp.). The oligonucleotides used as PCR primers 
were: (a) CIM4E3-FP, ~TGTACATCCTCACATC;  (b) CD44E16-RP 
ACTCCAACCTTCTTGACTCC;  (c)  CD44E7-FP,  CTCAGCAGGCTCd3- 
GACGG.  The PCR program was as follows: 94°C for 5 min; 35 cycles were 
carried out at 94°C for 30 s, 54°C at  1 min, 72°C at 1 rain 45 s. 
Ligand Blo  t 
2 #g of each recombinant CD44-1g fusion protein were separated by elec- 
trophoresis on a Tris/glycine 4-12% gradient gel (Novex, San Diego, CA), 
and transferred onto nitrocellulose. The membrane was blocked overnight 
at 4°C with 3% BSA 0.1% Tween-20 in PBS. The membrane was washed 
twice for 5 min in PBS, and then '~12 tzCI of the iodinated proteins were 
added in the blocking buffer for 1 h at RT. The nitrocellulose was washed 
five  times in PBS 0.1%  Tween-20 at  RT,  and then exposed to a  phos- 
phorimager screen overnight. The binding between the iodinated growth 
factors and the HS-modified CIM4 isoforms were blocked with heparin 
(Porcine Intestinal mucosal heparin; Sigma Immunochemicals) by prein- 
cubating 300/zg/ml of  heparin with the growth factor for 30 min before add- 
ing the mixture to the membrane. The heparin-binding control involved in- 
cubating  2  /~Ci of  each  iodinated  protein  with  either  Sepharose  or 
heparin/Sepharose (Sigma Immunochemicals). The Sepharose beads were 
washed five times in PBS at RT and the radioactivity measured in a gamma 
counter. 
ELISA 
Three concentrations of CD44V3VS-V10-Ig untreated and CD44V3V8-V10-1g 
digested with 4 mU of Flavobacterium  heparinum Heparitinase were im- 
mobilized to a Immulon 2 plate (Dynatech Laboratories, Chantilly, VA) in 
PBS overnight. The plate was blocked for 2 h with lx  Specimen Diluent 
(Genetic Systems, Seattle, WA). After washing the plate with 0.05 % Tween- 
20/PBS,  0,8  /zg/ml  of biotin-conjugated b-FGF  (Boehringer Mannheim 
Corp.) was added to the wells in the absence and presence of 3 mg/ml hepa- 
rin (Porcine Intestinal mucosal heparin; Sigma Immunochemicals) and in- 
cubated for 1 h at RT. The plate was washed, and then avidin-conjugated 
HRP (Sigma Immunochemicals) diluted with blocking solution 1:500 was 
added to the wells for 30 min at RT. The plate was washed and incubated 
with 100 #1 of EIA Chromgen Reagen (Genetic Systems) for 10 min at RT. 
The reaction was stopped by addition of 100/~1 of I N H2SO4 and the opti- 
cal density measured on an ELISA reader at dual  wavelengths 450 and 
630 nm. 
Northern Blot Analysis 
Total RNA was extracted in 4 M guanidine isothiocyanate (Fluka Chemical 
Corp.,  Ronkonkoma,  NY),  25  mM sodium citrate, 0.5 %  sarcosyl, and 
0.1 M/3-mercaptoethanol. 20 #g were fractionated on a 1% agarose-formal- 
dehyde gel  (38),  transferred to  a  nylon membrane  (Amersham Corp., 
Arlington Heights, IL) and hybridized to 32P-labeled probe as described 
(38).  The membranes were stained with methylene blue to ensure equal 
loading and transfer. 
Patients 
Patients with the classical T cell-mediated skin diseases allergic contact 
dermatitis (ACD, n  =  11) and psoriasis (PSO, n  =  8) were compared to 
normal control subjects (NS, n =  9). None of  the patients had received prior 
treatment for their skin condition. After informed consent, full thickness 
4-mm punch biopsies were obtained from the lesional skin of the patients. 
In the NS group, 4-mm punch biopsies were taken from the volar aspects 
of  the forearm. Samples were snap frozen immediately and stored at -80°C 
until further use. 
Immunohistochemistry 
Frozen skin specimens were embedded in Optimum Cutting Medium (Miles 
Inc., Elkhart, IN) and 5-#m serial cryostat sections were prepared using a 
Crycut 2000 (Reichert & Jung, Nul~bach, FRG). Air-dried, acetone-fixed 
frozen sections were stained using a four step immunohistochemical stain- 
ing protocol (ABC-technique, DAKO):  (a) primary mAb (rabbit IgG or 
mouse IgG); (b) biotin-conjugated goat-anti-mouse IgG, or biotin-conju- 
gated goat-anti-rabbit IgG; (c) peroxidase-conjngated streptavidin (d), and 
diamino-benzidine as chromogenic substrate. Finally,  sections were coun- 
terstained with hemalum. Control staining was performed by replacing the 
primary mAb with isotype-matched control reagents. Staining was evalu- 
ated by four independent observers in a blinded fashion using a Zeiss Ax- 
ioskop, equipped with a MC100 camera system. The opinions of the ob- 
servers were concordant. 
Results 
CD44-Ig Fusion Proteins Expressing 
Alternatively Spliced Exon V3 Are Modified 
with Heparan Sulfate 
Epithelial cells have been shown to express an HS-modified 
CIM4 isoform which contains the alternatively spliced exons 
V3-V10 (3,  30). Inspection of the amino acid sequence en- 
coded by genomic CIM4 revealed that there are six potential 
GAG attachment sites with the known consensus Ser-Gly. 
Four of the potential GAG attachment sites are in the "com- 
mon" region of CD44 and one each in exons V3 and V10. The 
motif  in  exon  V3  contains  a  Ser-Gly-Ser-Gly sequence 
whereas the five other potential GAG sites only contain Ser- 
Gly (47). Jackson et al. (20) have used Namalwa cell trans- 
fectants to characterize the GAG modifications of various 
CD44 isoforms and showed that CIM4 isoforms expressing 
V3 can be modified with HS. 
To confirm these  results  and  explore the possibility of 
using CD44-Ig fusion proteins to study the ability of HS- 
modified CD44 to present HS-binding growth factors, four 
CD44 expression constructs were made (Fig. 1). CD44H-Ig 
encodes  a  soluble  chimeric  protein  that  contains  all  the 
CD44  extracellular common exons  (El-E5,  El5,  El6)  in 
frame with the hinge, CH2, and CH3 domains of a human 
IgG,  (1). CD44E-Ig  consists  of all  the extracellular com- 
mon exons, as well as exons V8-V10, fused to the same hu- 
man IgG domains (51). CD44V3, V8-V10-Ig, and CIM4V3- 
V10-Ig  both encode for the common extracellular domain 
exons, the human antibody domains, and the variably spliced 
exons V3, V8-V10, and V3-V10, respectively. 
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four  CD44-Ig  constructs  used  in  these  studies;  CD44H-Ig, 
CD44E-Ig, CD44V3, V8-V10-Ig, and CD44V3-V10-Ig. Exon V3 is 
shaded since it contains a Ser-Gly-Ser-Gly motif which is a putative 
site for GAG attachment. 
COS  cells were transfected with the  four CD44-Ig chi- 
meric  constructs  and  metabolically  labeled  with  35SO4  -2. 
The four purified Ig fusion proteins were either left untreated 
or digested with chondroitin ABC lyase (ABC), heparitinase 
(HEP), or both lyases (Fig. 2, A and B). The majority of the 
35SO4  -2  is  incorporated  into  GAGs  such  that  the  proteins 
can be analyzed for the loss of label after digestion to deter- 
mine the type of GAG attached to the proteoglycan. Fig. 2, 
A and B show that CD44H-Ig and CD44E-Ig contain sulfate 
modifications that are sensitive to chondroitin ABC lyase but 
not to heparitinase digestion.  In contrast,  when COS cells 
were transfected with DNA encoding  CD44-Ig constructs 
containing  exon  V3,  the  35504  -2  modified  CD44  recom- 
binant proteins were sensitive to both heparitinase and chon- 
droitin ABC lyase (Fig. 2, Cand D). These data demonstrate 
that when exon V3 is present, COS cell-produced CD44-Ig 
fusion proteins are modified with heparan sulfate which is 
likely  attached  at  the  Ser-Gly-Ser-Gly motif in  exon  V3. 
Some  residual  35SO4  -2  label  remains  after  digestion  with 
heparitinase and chondroitin ABC lyase which is most likely 
keratin sulfate which is known to decorate CD44 (51). 
b-FGF and HB-EGF  Bind to HS-modified 
CD44 Isoforms 
To directly examine the ability of HS-modified CD44  iso- 
forms to bind heparin-binding growth factors, b-FGF, AR, 
and HB-EGF were iodinated and used in ligand-binding as- 
says.  We chose b-FGF for this study since its interactions 
with  HS  and  HS-modified proteoglycans  have been  thor- 
oughly  characterized.  An  HS-modified  CD44  isoform  is 
abundantly  expressed  in  keratinocytes  and  the  potential 
biological role for CD44 in keratinocyte growth seemed in- 
triguing (3,  12).  Therefore, AR and HB-EGF, two heparin- 
binding proteins, were analyzed since they are autocrine fac- 
tors for keratinocytes (7, 13, 39, 49). OM, a non-HS-binding 
protein,  was  also  iodinated  and  used  in  this  assay  as  a 
control. 
CD44-Ig, CD44E-Ig, CD44V3V8-VI0-Ig, and CD44V3- 
V10-Ig were produced in COS cells and their ability to bind 
b-FGF, HB-EGF, AR, and OM was examined. Shown in Fig. 
3 A are the different CD44 isoforms electrophoresed, trans- 
Figure  2.  GAG  modification  of  CD44  isoforms.  (A)  35SO4 2_ 
labeled CD44H-Ig, (B) CD44E-Ig, CD44V3, (C) V8-110-1g, and 
(D) CD44V3-V10-Ig  were recovered from the supernatant of COS 
cell transfectants, purified, and divided equally into four aliquots. 
One aliquot was left untreated, the others were digested for 1 h with 
HEP, chondroitin  ABC lyase (ABC), or with both.  The proteins 
were then resolved by SDS-PAGE and analyzed by radiography. 
terred to a  nitrocellulose membrane, and probed with  1251- 
b-FGF.  HS-modified  CD44  isoforms containing  variably 
spliced exon V3 bound the  '25I-b-FGF (Fig.  3,  lanes 3  and 
5).  Digestion with heparitinase abolished  '25I-b-FGF bind- 
ing  (lanes 4  and  6).  CD44H-Ig and CD44E-Ig which  are 
decorated with chondroitin sulfate (CS) did not bind L25I-b- 
FGF (lanes 1 and 2). These data indicate that the CD44 iso- 
forms modified with  HS but  not CS  can bind b-FGE  An 
identical  experiment  carried  out  with  ~2~I-HB-EGF also 
demonstrated that the interactions between CD44 and HB- 
EGF  were  HS  dependent  (Fig.  4).  The  specificity of the 
CD44/b-FGF  interaction  was  examined  by  the  following 
competition assays. Probing of the ligand blots in the pres- 
ence of 300 ~g/ml of heparin effectively blocked both ~2sI- 
b-FGF (Fig.  3  B) and  ~25I-HB-EGF (Fig.  4  B) binding  to 
HS-modified  CD44  isoforms.  Approximately  100-fold 
excess unlabeled b-FGF was used to compete the binding 
of  ~25I-b-FGF to  the  HS-modified  CD44  isoforms;  some 
nonspecific background binding can be seen in lane 1 (Fig. 
3 C). To further examine the specificity of these interactions, 
an ELISA approach was used which demonstrated a concen- 
tration and HS dependents for CD44 and b-FGF interactions 
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CD44  proteins were resolved by  SDS-PAGE, transferred to  a 
nitrocellulose membrane, incubated with t25I-b-FGF, washed, and 
analyzed by radiography. (A) CD44H-Ig, CD44E-Ig, CD44V3, V8- 
V10-Ig, and CD44V3-V10-Ig  alone or treated with HEP (+). (B) 
CD44 V3, V8-V10-Ig,  and CD44 V3-V10-Ig  were analyzed for bind- 
ing of ~25I-b-FGF in the presence of 300 #g/ml of heparin.  (C) 
CD44V3, V8-VI0-Ig,  and CD44V3-V10-Ig  were analyzed for bind- 
ing 125I-b-FGF in the presence of a  100-fold excess of unlabeled 
b-FGE (D) CD44 was immunoprecipitated from NHEK and ana- 
lyzed for binding t25I-b-FGF. 
Figure 4. Binding of HB-EGF to HS-modified CD44. (A-B)Pu- 
rified CD44 proteins were resolved by SDS-PAGE, transferred to 
a nitrocellulose membrane, incubated with 12~I-Hb-FGF, washed, 
and analyzed by radiography. (A) CD44H-Ig, CD44E-Ig, CD44V3, 
V8-VI0-Ig,  and CD44V3-V10-Ig  alone or treated with HEP (+). (B) 
CD44V3, V8-VI0-Ig,  and CD44V3-V10-Ig  were analyzed for bind- 
ing of 125I-HB-EGF in the presence of 300/~g/ml of heparin. 
(Fig.  5). CD44V3V8-V10-Ig was immobilized onto a 96-well 
plate and the binding of biotin-conjugated b-FGF was exam- 
ined.  The binding of b-FGF was concentration dependent 
(open bars),  and effectively competed by 3 mg/ml of heparin 
(striped bar).  Furthermore, digestion of CD44V3V8-V10-Ig 
with heparitinase also abolished the binding (black bars). 
Normal  human  epithelial  keratinocytes  (NHEK)  have 
been shown to express a HS-modified CD44 isoform (12). 
To show that the ability of HS-modified CD44 to bind b-FGF 
was not a property unique to the fusion protein, CD44 im- 
munoprecipitated from NHEK was tested for its capacity to 
interact  with  ~25I-b-FGF. Fig.  3  C  shows that  CD44 pro- 
duced  by  NHEK can  bind  t25I-b-FGE  This  demonstrates 
that HS-modified CD44 expressed either as a recombinant 
immunoglobulin fusion protein in COS cells or as an endog- 
enous membrane bound protein  in NHEK is  able to bind 
b-FGE 
~25I-AR and t25I-OM did not bind to any of the CD44 iso- 
forms tested (data not shown). To determine if AR was still 
able to bind HS after iodination, 2 #Ci of all four of the iodi- 
nated proteins were incubated with Sepharose and heparin 
Sepharose beads for 1 h, and then washed.  ~25I-b-FGF, !25I  - 
HB-EGF,  and  ~25I-AR bound  substantially  more  to  the 
heparin Sepharose demonstrating that the iodination had not 
inhibited  the  ability  of  AR  to  bind  heparin,  whereas 
t25I-OM did not show a  similar increase in binding to the 
heparin Sepharose (Table I). While  ~25I-AR is able to bind 
to  the  heparin  Sepharose beads  but  not the  HS-modified 
CD44,  it  cannot be  ruled  out that  the  ~2~I-AR is  able  to 
function in a ligand blot format. However,  the experiments 
with AR were repeated numerous times and strongly suggest 
that it does not bind to the HS attached to CD44 made in 
COS cells. 
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CD44V3V8-V10-Ig (open bars) bound  biotin-conjugated  b-FGF 
in a  concentration-dependent  manner.  (Striped bars) Binding is 
blocked in the presence of 3 mg/ml heparin. (Black  bars) Hepariti- 
nase digestion of CD44V3V8-V10-Ig abolished b-FGF binding. 
In Vitro-activated Endothelial Cells Express CD44 
To examine the proposed role of CD44 in the presentation 
of HS-binding chemokines to leukocytes along activated vas- 
cular endothelium, a number of experiments were conducted 
to determine which CD44 isoforms are expressed by acti- 
vated  endothelial  cells  and  if  these  CD44  isoforms  are 
modified with GAG. The first level of analysis involved an 
examination  of the  expression  of  CD44  in  cultured  en- 
dothelial cells.  It had been previously reported by Mackay 
and colleagues that endothelial  cells express low levels of 
CD44 which can be upregulated after activation with TNF-~ 
(37). In our hands, cultured HUVEC constitutively express 
high levels of CD44, the expression of which is not further 
upregulated after treatment for 6 h with TNF-a, IL-1, LPS, 
INF-% thrombin, or histamine (Fig. 6). Also, no changes in 
the levels of CD44 expression were observed when the cells 
were treated with TNF-c~ for various time periods between 
30 min and 96 h (Fig. 6). These experiments were done with 
two different donors; in both cases we observed that under 
our  culture  conditions  CD44  is  abundantly  expressed by 
HUVEC cells and that additional stimulation does not result 
in higher levels of CD44 expression. This difference might 
be due to differences in the growth factors added to the media 
Table L  Binding of Iodinated Proteins  to Heparin 
cpm  ~25I-b-FGF  ~2~I-AR  ~25I-HB-EGF  ~2sOM 
Sepharose  1,761  6,137  18,279  19,943 
Sepharose  63,932  83,815  173,105  13,632 
+ Heparin 
2 ~Ci of each iodinated  protein was added to Sepharose and heparin Sepharose 
beads for  1 h, and then washed and counted. 
Figure 6. Expression of CD44 protein by cultured endothelial cells. 
HUVEC were cultured in the presence of the indicated proinflam- 
matory mediators, lifted with EDTA, and stained with isotype con- 
trois, anti-CD44 mAb A3D8, and anti-ELAM-1. The bar graph sets 
the expression level of the unstimulated cells to 100%. Unstimu- 
lated cells and the stimulated cells expressed abundant CD44.  Un- 
stimulated HUVEC did not express ELAM-1, but upon activation 
was strongly unregulated. 
used to maintain these primary cells in culture in different 
laboratories.  However, it  should be  noted that these cells 
have not become refractory to activation by these proinflam- 
matory mediators which are still able to direct the expres- 
sion of other inducible cell adhesion molecules. For exam- 
ple,  TNF-ct  treatment  of these  cells  results  in  E-selectin 
expression (Fig. 6). Taken together, the results of Mackay et 
al. (37) and the data presented herein show that activated en- 
dothelial cells express CD44. 
Northern blot analysis of human aortic endothelial cells 
(HAEC) activated with b-FGF, ~FGF, TGF-~, or TNF-c~ for 
48  h  confirmed that  in  our  culture  conditions  CD44  was 
abundantly  expressed  before and  after  stimulation  in  en- 
dothelial cells (data not shown). 
Activated Endothelial Cells Do Not Express CD44 
Isoforms Containing 113 
As  demonstrated by Jackson et al.  (20)  and  corroborated 
above, CD44 isoforms containing exon V3 can be modified 
with HS. Based on the proposed role of HS-modified CD44 
in the presentation of HS-binding chemokines to lympho- 
cytes by activated endothelial cells, we examined the ability 
of activated endothelial cells to express CD44 isoforms con- 
taining exon V3 by flow cytometry using an anti-V3 specific 
antibody.  HUVEC  cells were stained  with either an anti- 
CD44 mAb which recognizes all CD44 isoforms or with an 
antibody which recognizes an epitope present only in V3 and 
analyzed by flow cytometry. As shown in Fig. 7 A, HUVEC 
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cultured epithelial and endothelial cells. Line drawings represent- 
ing flow cytometry profiles of cells expressing CD44. (A-D) Cul- 
tured endothelial cells from pooled donors were stained with either 
isotype-matched controls (shaded  profile) and a mAb for either the 
"constant" region of CD44 (A and C) or a mAb specific for CD44 
exon V3 (B and D). A and B represent profiles from unstimulated 
cells, while C and D are FACS profiles from cells stimulated with 
TNF-c~ for 48 h. NHEK were stained with either a mAb to the con- 
stant region of CIM4 (E) or with a mAb for CD44 exon V3 (F). 
express abundant levels of CD44 but do not bind to the anti- 
body recognizing exon V3 (Fig. 7 B). Treatment with TNF-ot 
for 48 h did not change the binding profiles of these two anti- 
bodies (Fig. 7,  C and D).  Similar antibody-binding experi- 
ments on keratinocytes showed that these cells express abun- 
dant levels of CD44 which contain exon V3 (Fig. 7, E  and 
F). These results show that activated endothelial cells do not 
express CD44 isoforms containing V3. 
Analysis of CD44 RNA Transcripts 
in Endothelial Cells 
To  investigate the  presence  of RNA  transcripts  encoding 
different CD44 isoforms in activated endothelial cells,  RT- 
PCR was carded out.  Since NHEK are known to express 
CD44  isoforms with  alternatively spliced exons,  we used 
these cells as a control throughout our experiment. RT-PCR 
was carried out on RNA isolated from NHEK, human mam- 
mary epithelial cells (HMEC), HAEC, and HUVEC using 
PCR  primers  located  in  the  common  exons  E3  (forward 
primer) and El6 (reverse primer, Fig. 8 A). As shown in Fig. 
Figure 8. Expression of CD44 variably spliced exons by cultured 
epithelial and endothelial cells. (,4) Line drawing representation of 
the extraceUular domain exons of CD44. El-E5 and e15-E16 repre- 
sent  the  common exons  shared  by all  CD44  isoforms.  V1-V10 
represents potential alternatively spliced exons. Arrows represent 
the forward (CD44E3-FP) and reverse (CD44E16-RP) primers that 
were used to generate RT-PCR bands shown in B. (B) RT-PCR was 
carried out on the indicated cell types and prointtammatory media- 
tors were added to HUVEC for 6 h, the PCR products were frac- 
tionated on a 2 % agarose gel and stained with ethidium bromide. 
(C) The PCR products were transferred to a nylon membrane and 
probed with a 32P-random primed probe to CD44E. 
8 B, PCR products obtained from NHEK form a DNA ladder 
which can be detected both in the ethidium bromide-stained 
gel (Fig.  8 B) and in the corresponding DNA blot probed 
with a 32p-labeled CD44E cDNA (Fig. 8 C). The same pat- 
tern of CD44 isoform expression is seen in normal HMEC. 
These data confirm that NHEK express CD44 isoforms con- 
taining  alternatively  spliced  exons  and  demonstrate  that 
HMEC  ceils also express alternatively spliced CIM4 iso- 
forms. In contrast, cultured HAEC and HUVEC generated 
a single-sized DNA of 543 bp, the predicted size for CD44H 
(Fig.  8, B  and C).  The PCR product was purified and se- 
quenced to confirm that it did not contain any alternatively 
spliced  exons  (data  not  shown).  As  a  second  control,  a 
CD44E clone was used for PCR analysis and generated a 
band of 894 bp, the expected size for a CD44 isoform con- 
taining the variably spliced exon VS-V10 (Fig. 8, B and C). 
Stimulation of HUVEC for 6 h  with a  number of different 
proinflammatory mediators (TNF-ot, Histamine, Thrombin, 
LPS, IFN-% IL-1) did not induce the expression of alterna- 
tively spliced CD44 isoforms (Fig.  8, B  and C). 
RT-PCR was used to specifically look for the expression 
of CD44 transcripts containing exon V3 in the following cell 
types: HUVEC, HMEC, NHEK, a fibroblast cell line WI- 
38, and HT-1080 cells (fibrosarcoma ceils). Two RT-PCR ex- 
Bennett et al.  CD44V3 lsoforms  Present  Heparin-binding  Proteins  693 Figure 9. Expression of CD44 transcripts encoding V3 by cultured 
epithelial and endothelial cells. (A) Line drawing representation of 
the extracellular domain exons of CD44. El-E5 and E15-E16 repre- 
sent the  common exons shared  by all  CD44  isoforms. V1-V10 
represents potential alternatively spliced exons. Arrows represent 
the three different primers used for RT-PCR: two of the primers are 
to common exons CD44E3-FP, CD44E16-RP; and forward primer 
CIM4V3-FP is to the variably spliced exon V3. (B) RT-PCR  prod- 
ucts were run on a 2 % agarose gel and stained with ethidium bro- 
mide. (C) The gel was transferred to a nylon membrane and probed 
with a 32P-end-labeled oligonucleotide to V3. 
periments were carried out, the first using the primers lo- 
cated in E3 and El6 described in Materials and Methods; the 
second using a primer located in V3 (forward primer) and 
the El6  (reverse primer) also described in  Materials  and 
Methods (Fig. 9 A). In both cases the presence of V3 in the 
PCR products was examined by Southern blot using a 32p_ 
labeled probe specific to exon V3. Fig. 9, B and C show that 
exon  V3  is  present  in  the  PCR  product  generated  from 
NHEK and HMEC. PCR primers E3/E16 gave rise to PCR 
products with the predicted size for CD44H (Fig. 9 B) using 
RNA  isolated  from HUVEC,  WI-38,  and  HT-1080 cells. 
These PCR products did not bind to the V3 specific probe 
(Fig.  9  C).  PCR primers V3/E16  failed to generate PCR 
products when RNA  from HUVEC,  WI-38,  and HT-1080 
cells were used as determined by ethidium bromide staining 
(Fig.  9  B) and probing with the radiolabeled V3  specific 
probe (Fig. 9  C).  These same primers gave rise to the ex- 
pected PCR product using RNA isolated from NHEK and 
HMEC cells (Fig. 9 B) which bound to the V3 specific probe 
(Fig.  9  C).  As expected, a  control sample using  CD44E 
cDNA gave rise to a PCR product of the expected size when 
the E3/E16 primers were used, which did not bind to the V3 
specific probe, and failed to generate PCR products when the 
V3/E16 primers were used. 
Expression of CD44 lsoforms Containing Variably 
Spliced Exons in Inflamed Skin 
In the experiments described above we used cultured en- 
dothelial cells and keratinocyte cells to examine the expres- 
sion of CD44 isoforms containing variably spliced exons. To 
determine if these observations reflect what is found in vivo, 
we examined the expression of CD44 containing variably 
spliced exons (CD44V) in keratinocytes, endothelial cells, 
monocytes, and dendritic cells found in inflamed skin by im- 
munohistology. Tissue from two classical T  cell-mediated 
inflammatory skin diseases, i.e., allergic contact dermatitis 
and  psoriasis  were  examined  for CD44V-expression.  No 
CD44V  staining could be detected on dermal endothelial 
cells  using  either  a  polyclonal  Ab  directed  against  all 
CD44V,  including V3  (15),  or mAb-specific for CD44-V5 
and CD44-V6 (29) (Fig.  10, A-C).  This lack of CD44V ex- 
pression was observed even in the presence of dense perivas- 
cular lymphocytic infiltrates (Fig.  10) and was identical to 
that of normal skin (data not shown). In contrast, we found 
that these reagents clearly detect CD44 isoforms containing 
variably spliced exons expressed by epidermal keratinocytes 
and activated macrophages and dendritic cells in the same 
specimen (Fig.  10) with keratinocytes expressing abundant 
amounts of a  CIM4  isoform containing V3.  In agreement 
with what had been previously reported by Heider et al. (14), 
we find that endothelial cells express low levels of a CD44 
which is recognized with an antibody which binds to an epi- 
tope in the common exons (Simon, J., and E. Tanczos, un- 
published). 
GAG Modification of Endothelial Cell CD44 
Finally, we examined whether CD44 expressed on HUVEC 
is  modified with  glycosaminoglycans.  In  this  experiment 
NHEK,  HT-1080 cells,  and  HUVEC  were  metabolically 
labeled with 35SO4  -2 for 4  h,  immunoprecipitated with an 
anti-CD44 mAb, analyzed by SDS-PAGE, and followed by 
autoradiography. No detectable "SO4  -2 modified CD44 was 
obtained from endothelial cells (data not shown) but very 
strong  signals  were detected from CD44  immunoprecipi- 
tared from HT-1080 cells (Fig. 11 B) and NHEK (Fig. 11 C). 
Extending the labeling time from 4  h  to  16 h  for the en- 
dothelial cells resulted in the detection of a very low amount 
of 35SO4-2-1abeled CD44 when the gel was exposed to film 
for a prolonged time period (Fig.  11  A),  Digestion of the 
35SO4-2-1abeled CD44  obtained  from  HT-1080 cells  with 
chondroitin ABC lyase removed all of the label suggesting 
that in these cells,  which express predominantly CD44H, 
CD44 is modified with CS (Fig.  11 B). Digestion of CD44 
obtained from the NHEK with chondroitin ABC lyase and 
heparitinase removed 70%  of the label suggesting that the 
CD44  expressed  by  these  cells,  which  contains  V3,  is 
modified with both CS  and HS  (Fig.  11  C).  In  contrast, 
digestion of CD44 immunoprecipitated from HUVEC with 
both chondroitin ABC lyase and heparitinase did not result 
in any detectable loss of label even after overexposure of the 
gel  (Fig.  11  A).  Treatment of the  endothelial  cells  with 
TNF-c~, histamine, IL-1, LPS, INF-% and thrombin for 48 h 
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skin. (A) Acute allergic contact dermatitis:  CD44V is expressed by keratinocytes  in the epidermis but not by dermal endothelial  cells (arrow- 
heads) (CD44V poly); (B) allergic contact dermatitis:  C D44V5 is expressed by keratinocytes  in the epidermis but not by dermal endothelial 
cells (arrowheads) (VFF8); and (C) psoriasis: CD44V6 is expressed  by keratinocytes  in the epidermis and by dermal macrophages and 
dendritic cells  (arrowheads) but not by dermal endothelial  cells  (small arrows) (VFF7). Bars: (A) 100 #m; (B and C) 63 #m. 
and  labeling  with  35SO4  -2  for  16 h  also resulted  in only a 
minimal amount of label incorporated into the immunopre- 
cipitated  CD44  (data not shown). 
Discussion 
Expression of different CD44-Ig constructs in COS cells has 
allowed us to establish that CD44 isoforms containing vari- 
ably spliced exon V3 can be modified with HS. These results 
are in agreement with the findings of Jackson et al. (20) who 
extensively characterized the GAG modifications of differ- 
ent  CD44  isoforms.  Selected  serine  residues  are  used  by 
xylosyltransferase to initiate GAG chain elongation, and at- 
tempts to define consensus recognition sequences surround- 
ing the  serines  have been  made  (for  review  see  26).  Ser- 
GIy-X-Gly preceded  by  acidic  residues  is  recognized  by 
xylosyltransferase in a number of GAG-substituted proteins, 
and synthetic peptides.  There are also a number of proteins 
that do not contain the above consensus at sites of GAG at- 
tachment;  for example,  some proteins have GAGs attached 
to serines in the context of only Ser-Gly. While there are six 
potential  GAG attachment  sites  in CD44,  five of the  sites 
constitute the most minimal consensus Ser-Gly and some of 
these sites are modified by chondroitin sulfate.  In contrast, 
exon V3 has a  Ser-Gly-Ser-Gly motif.  The data presented 
herein and that presented  by Jackson et al.  (20)  show that 
this site can be modified with heparan sulfate in a variety of 
cell  types.  The relationship  between  the protein  backbone 
and the type of GAG added is presently not understood, but 
there is increasing evidence that there are determinants that 
reside in the proteoglycan core protein which influence this 
Figure I1.  GAG modification  of CD44 expressed  by cultured  epi- 
thelial and endothelial cells. (A) HUVEC were labeled for 16 h with 
35SO4  -2, immunoprecipitated  with an anti-CD44 mAb (pgp-1), the 
sample  was divided  in two,  half of the sample  was digested  with 
both HEP and chondroitin ABC lyase (ABC),  and then both sam- 
pies were run on SDS-PAGE and analyzed by radiography.  (B) HT- 
1080 cells were labeled  for 4 h with 35SO,  -2, immunoprecipitated 
with an anti-mAb (pgp-1), the sample was divided  in two, half of 
the sample  was digested  with chondroitin ABC lyase (ABC), and 
then both samples were run on SDS-PAGE and analyzed by radiog- 
raphy. (C)NHEK were labeled  for 4 h with 35SO4  -2, immunopre- 
cipitated  with an anti-CD44 mAb (pgp-1), the sample was divided 
in two, half of the sample was digested  with both HEP and ABC, 
and then both samples  were run on SDS-PAGE and analyzed by 
radiography. 
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Kokenyesi and Bernfield who present data that suggest that 
the Ser-Gly-Ser-Gly motif in syndecan is modified with HS 
while the Ser-Gly motifs are modified with CS (28). 
Understanding the multiple functions of the various CD44 
isoforms is the focus of intensive research. The role of pro- 
teoglycans as reservoirs of and presenters of glycosamino- 
glycan-binding growth factors, cytokines, and chemokines is 
well established (for review see 21, 27, 55, 63).  Recently, 
Shaw and colleagues have shown that GAG-modified CD44 
isolated from peripheral blood monocytes is able to bind and 
present MIP-1/3 to T cells and induce their ability to bind 
VCAM-1 in vitro (53).  Here we show that only CD44 iso- 
forms containing variably spliced exon V3 are modified with 
HS and can present some, but not all, HS-binding growth 
factors. More specifically, we found that HS-modified CIM4 
can bind to b-FGF, and HB-EGF but not to AR. Only CD44 
isoforms containing exon V3  become decorated with HS. 
Heparitinase digestion and free heparin abolished the inter- 
action between the  HS-modified CD44  isoforms and the 
growth  factors  demonstrating that  these  interactions  are 
specifically mediated by HS. Furthermore, other GAGs such 
as CS do not participate in the interactions since CD44 iso- 
forms modified by CS  did not bind to any growth factor 
tested.  The culmination of numerous approaches used to 
identify the heparin-binding domain of b-FGF has demon- 
strated that the binding domain is composed of a discontinu- 
ous set of amino acids, and that the majority of the binding 
free energy is contributed by hydrogen bonding and van der 
Waals packing (57) providing for very specific interactions. 
In addition, synthetic peptides and mutagenesis studies have 
been used to begin to identify the heparin-binding domain 
of HB-EGF (58),  whereas the AR heparin-binding domain 
at this point can only be speculated. To fully understand the 
specificity of binding by these three proteins to the heparan 
sulfate on CD44 will require a complete characterization of 
their heparin-binding domains. 
The structural diversity of the HS moieties added to pro- 
teins is well documented; greatly varied is the number of 
glucuronic acid moieties epimerized to iduronic acid, and 
the degree and placement of sulfates, giving rise to very het- 
erogeneous molecules (for review see 26). This diversity in 
HS gives rise to domains with unique structures that provide 
specificity for interacting with different  HS-binding proteins. 
The best studied example of  the specificity of  the interactions 
between a heparin-binding protein and different heparan sul- 
fate structures is the interaction between antithrombin HI 
and its pentasaccharide target. These studies have shown that 
a  small subset of HS-modified proteoglycans contain the 
appropriate  pentasaccharide  (23,  36).  Furthermore,  the 
binding affinity of antithrombin 11I for different HS-proteo- 
glycans made in the same cell can vary greatly, suggesting 
that structural determinants in the protein backbone dictate 
the type of GAG biosynthesis and modifications that take 
place (40).  The specificity of the interaction of b-FGF with 
HS  was  first demonstrated by showing that the extent of 
b-FGF binding depended upon the HS source; HS from pig 
aorta bound substantially more to b-FGF than did HS from 
mouse Engelbreth-Holm-Swarm tumors  (11).  The  identi- 
fication of the minimal hexasaccharide required for maximal 
binding confirms the specificity of the interactions (19, 60, 
61). These results are consistent with our observation that 
COS cell-produced CD44 isoforms containing V3,  which 
are modified with HS, can differentially  interact with various 
HS-binding proteins. Our finding that HS-modified CD44 
produced by keratinocytes can bind to b-FGF further sug- 
gests that in these cells CIM4 may participate in the presen- 
tation of HS-binding  growth  factors,  chemokines and/or 
cytokines, and provide further activation signals to leuko- 
cytes during an inflammatory response in the skin. In addi- 
tion, the binding of HB-EGF to HS-modified CD44 suggests 
an important role for CIM4 in keratinocyte growth since 
HB-EGF is a keratinocyte autocrine growth factor (13). 
The ability of GAG-modified CD44 to bind and present 
HS-binding proteins to leukocytes has led to the proposition 
that this proteoglycan might play a role in the presentation 
of chemokines by inflamed vascular endothelial ceils. FACS, 
Northern blot, and PCR analysis demonstrated that cultured 
endothelial ceils express  abundant CD44H.  However,  we 
found no evidence that CD44 isoforms containing variably 
spliced exons were expressed by these cells even after treat- 
ment with proinflammatory mediators such as TNF-ct, IL-1, 
INF-% histamine, thrombin, or LPS.  This observation is 
consistent with our finding that in the inflamed skin from pa- 
tients with ACD or PSO vascular endothelial cells do not ex- 
press  CD44  isoforms containing variably  spliced  exons. 
These  results  in conjunction with the  data described  by 
Heider et al. (14) who showed that endothelial cells in nor- 
mal tissue samples express low levels of CD44 containing 
no variably spliced exons, and the data of Mackay et al. (37) 
which showed that CD44 expression could be upregulated 
after endothelial cell activation suggest that only expression 
of CD44H is upregulated after endothelial ceil activation in 
vivo. Furthermore, we also showed that exon V3, which pro- 
vides the required sequence motif for the modification of 
CD44 with HS, was not expressed by activated endothelial 
cells. These results suggest that CD44 is not one of the pro- 
teoglycans involved in the presentation of HS-binding che- 
mokines to leukocytes on inflamed vascular endothelium. 
This interpretation is supported by the identification of the 
major HS-modified proteoglycans from HAEC and HUVEC 
which included syndecan, glypican, fibroglycan, and perle- 
can, but not CD44 (40). 
Although  CD44H  is  not modified with  HS  it  can  be 
modified with  CS.  Metabolic-labeling  experiments  with 
35SO4  -2  demonstrated that CD44H  expressed by activated 
endothelial cells is not extensively modified with GAGs. Al- 
though we cannot rule out the possibility that endothelial cell 
proteoglycans are not easily labeled using this protocol, our 
data suggest that on activated endothelial ceils CD44H is not 
a GAG-modified  proteoglycan. This data is supported by the 
observations of Bourguignon et al. (2) who showed by cell 
surface labeling endothelial ceils with 1251 that CD44 is ex- 
pressed as a  ll6-kD glycoprotein, and not as larger more 
diffuse molecules characteristic of GAG modifications. 
In  summary,  this  report  provides  direct evidence that 
CD44 isoforms containing variably spliced exon V3 can bind 
to a subset of HS-binding growth factors. A more thorough 
examination of the cell types that express CD44V3 isoforms 
and the HS-binding proteins which CD44 presents during 
development, tumor growth and metastasis, and other hyper 
proliferative diseases  such as inflammatory skin diseases 
will likely reveal that CD44 contributes a critical function 
for these biological processes. 
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